Mitochon Pharmaceuticals is a clinical stage biotech company developing drugs that target the mitochondria for neurodegenerative diseases.

Mitochon Pharmaceuticals is a start-up biotech company, formed in 2014, that focuses on developing drugs that target the mitochondria for a host of serious diseases with significant unmet medical needs. The company’s development programs are primarily focused on neurodegenerative & neuromuscular diseases including: Huntington’s, Batten Disease, Stroke, Duchenne Muscular Dystrophy (DMD), Alzheimer’s Disease, Parkinson Disease and severe burns, and secondarily on metabolic disorders due to over-nutrition (diabetes, obesity and NASH). On-going research has linked these diseases to various malfunctions of the mitochondria. By correcting them, Mitochon aims at opening the way for a broad range of disease modifying therapies.

Sector: Healthcare
Sub Sector: Small Molecule (Chemical Entity) Therapeutics & Formulation
Industry: Healthcare
Status: Active
County: Montgomery

Contact Information

Robert Alonso

Founder and CEO

John Geisler

Founder and CSO

Marcus Keep